Pink Dx is a discovery-stage diagnostics company focusing on women’s health.

Many patients are only diagnosed with cancer after a diagnostic odyssey that is lengthy, expensive, and inefficient. This is particularly true in cancers affecting the female reproductive system, for which the standard of care involves transvaginal sonography, which has low predictive value and a high rate of failure among other limitations. In contrast, Pink Dx is developing a minimally-invasive test with superior performance that is easy to administer, thus reducing the number of unnecessary biopsies and hysteroscopies.